Study Name:
KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
Targeted Disease(s):
Lung Cancer
Purpose of Study:
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn 1) about the safety of MK-1084 and if people tolerate it when taken with other treatments and 2) how many people have the cancer respond (get smaller or go away) to the treatments.
Study Dates:
April 30, 2026 - August 11, 2031
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT07286149
